Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

Publication

Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.

Journal Paper/Review - Apr 26, 2022

Achard Vérane, Putora Paul Martin, Zwahlen Daniel, Couñago Felipe, Scorsetti Marta, Eito Clara, Barrado Marta, Zapatero Almudena, Muto Paolo, Van De Voorde Lien, Lamanna Giorgio, Koutsouvelis Nikolaos, Dipasquale Giovanna, Ost Piet, Meersschout Sabine, Guckenberger Matthias, Jaccard Maud, Vanhoutte Frederik, Siva Shankar, Heikkilä Reino, Dirix Piet, Liefhooghe Nick, Otte François-Xavier, Gomez-Iturriaga Alfonso, Berghen Charlien, Shelan Mohamed, Conde-Moreno Antonio, López Campos Fernando, Papachristofilou Alexandros, Zilli Thomas

Citation

Achard V, Putora P, Zwahlen D, Couñago F, Scorsetti M, Eito C, Barrado M, Zapatero A, Muto P, Van De Voorde L, Lamanna G, Koutsouvelis N, Dipasquale G, Ost P, Meersschout S, Guckenberger M, Jaccard M, Vanhoutte F, Siva S, Heikkilä R, Dirix P, Liefhooghe N, Otte F, Gomez-Iturriaga A, Berghen C, Shelan M, Conde-Moreno A, López Campos F, Papachristofilou A, Zilli T. Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial. Radiother Oncol 2022; 172:1-9.

Type

Journal Paper/Review (English)

Journal

Radiother Oncol 2022; 172

Publication Date

Apr 26, 2022

Issn Electronic

1879-0887

Pages

1-9

Brief description/objective

Aim of this study is to report the results of the radiotherapy quality assurance program of the PEACE V-STORM randomized phase II trial for pelvic nodal oligorecurrent prostate cancer (PCa).